Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4825556 | 0.88 | HPGD (0.44) | HPGDKDM4EALDH1A1HSD17B10F2 | |
| SCHEMBL4817684 | 0.80 | HPGD (0.57) | HPGDKDM4ESMN1; SMN2RECQL | |
| SCHEMBL4598779 | 0.80 | KDM4E (0.47) | HPGDKDM4EALDH1A1HSD17B10F2 | |
| SCHEMBL4819428 | 0.74 | ADAM17 (0.44) | — | |
| SCHEMBL4611701 | 0.74 | RAB9A (0.51) | KDM4EALDH1A1F2 | |
| SCHEMBL15577710 | 0.73 | MAPK1 (0.46) | KDM4EALDH1A1TACR1SMN1; SMN2 | |
| SCHEMBL4824944 | 0.71 | HSD17B10 (0.42) | HPGDKDM4EALDH1A1HSD17B10F2 | |
| SCHEMBL4598287 | 0.71 | ALOX5AP (0.60) | HPGDALDH1A1HSD17B10TAAR1SMN1; SMN2 | |
| SCHEMBL4821439 | 0.70 | RAB9A (0.67) | HPGDALDH1A1TAAR1SMN1; SMN2 | |
| SCHEMBL4827389 | 0.68 | HPGD (0.67) | HPGDALDH1A1SMN1; SMN2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | HPGD 3156/4885KDM4E 2332/4885ALDH1A1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.